Clinical trial
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Enicepatide Versus Tirzepatide Among Participants With Type 2 Diabetes and Inadequate Glycemic Control on Oral Glucose-Lowering Medications
NCT07889648 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Enicepatide Versus Tirzepatide Among Participants With Type 2 Diabetes and Inadequate Glycemic Control on Oral Glucose-Lowering Medications
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- April 23, 2029
- Enrollment
- 948 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes mellitus
Lead sponsor's other trials
Hoffmann-La Roche, most recent start first.
+2,095 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,316 more trials See the condition page